Aktuellt
SENASTE
Redeye endorses today’s news that Nanexa has signed an evaluation agreement with a global pharma company regarding using Pharmashell to develop a long-acting formulation of a monoclonal antibody, a field that Nanexa previously has indicated increased interest in (and prepared its facility for). We currently mainly regard evaluation agreements as an option for further upside (beyond the Novo Nordisk evaluation) and thus see this agreement as a positive development for the company and share price. We hope to learn more about the evaluation soon, and potentially also to see one of the current evaluations materializing into a more extensive agreement.
LÄS MER
